This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Intuitive Surgical Is a High-Risk Stock Delivering Little Reward

 

NEW YORK (TheStreet) -- Shares of Intuitive Surgical (ISRG) , a company that specializes in robot-assisted surgeries, have been on fire since the stock bottomed out at $376 on July 17. In a little over a month, investors have seen their wealth grow by roughly 27%.

The stock, at around $479, is up nearly 25% on the year to date, 3% less than the gains seen since July. This has raised questions as to whether these gains can hold. I don't see a scenario where that's possible -- at least not in the near term.

Trading at a price-to-earnings ratio of 35, these shares aren't cheap.

Read More: Warren Buffett's Top 10 Dividend Stocks

Intuitive enjoys a P/E that is 11 points higher than the industry average of 24, according to Yahoo! Finance. This makes no sense when investors can buy Covidien (COV) and St. Jude Medical (STJ) at much cheaper valuations. Both St. Jude and Covidien trade at P/Es that are 10 points less. Not to mention they both pay a respectable yield of more than 1.5%, compared to no dividend for Intuitive.

In the case of Intuitive, bulls insist they're paying for growth. With a P/E of 35 that's exactly what one should expect. But that's not what's happening. The company just posted a 12% year-over-year revenue decline.

This means investors are willing to pay eight times sales for a company that's also suffering from gross margin compression. That's a risky proposition. Gross margin just fell roughly three points year over year, missing Wall Street's estimates by almost one full point. With operating income declining 35% year over year, investors should ask, where's the value?

A company representative was not available for comment.

Although Intuitive's strong position in robotic surgeries has major growth opportunities, including areas like Japan and other markets, the company's current performance doesn't yet jibe with the stock price. I worry that investors are bidding up these shares before the market realizes its mistake.

Intuitive's da Vinci robot, which is regarded the best in the industry, is not alone anymore. Johnson & Johnson (JNJ) is now getting in the action and is working on its own surgical robot, ones that are smaller than da Vinci and more mobile.

Read More: Your September Biotech Back-to-School Calendar

I'm not suggesting Johnson & Johnson will immediately knock off Intuitive. But that doesn't matter. What I think is important to consider here is the extent to which Johnson & Johnson can enter the market and steal any share at all. It doesn't have to be the leader.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs